Monoclonal Antibody Treatment Found Effective Against COVID-19
The New England Journal of Medicine published an Original Article on July 14, 2021, 'Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.'
This study found 'Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19–related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load.'
A total of 1,035 patients underwent randomization and received an infusion of bamlanivimab–etesevimab or placebo. The mean age of the patients was 53 years.
By day 29, a total of (2.1%) in the bamlanivimab–etesevimab group had a Covid-19–related hospitalization or death from any cause compared with (7%) in the placebo group.
Moreover, no deaths occurred in the bamlanivimab–etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19–related.
And at day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than those who received placebo.
'Although the results presented here are a step forward in the fight against Covid-19, considerable logistic challenges remain for the administration of monoclonal-antibody treatment,' concluded these researchers.
Bamlanivimab (LY-CoV555) is an investigational neutralizing IgG1 monoclonal antibody directed against the spike protein SARS-CoV-2 coronavirus. Bamlanivimab was designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19.
This study was supported by Eli Lilly, the owner of Bamlanivimab.